Pharvaris N.V.
PHVS
Positions held
Your positionsPHVS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Pharvaris N.V. operates in the biotechnology sector, which is known for its potential to deliver groundbreaking therapies and innovations, attracting significant investor interest.
- The company's market cap is approximately $2.18 billion, indicating a substantial valuation in the biotech space.
- Pharvaris has a strong buy recommendation with a target mean price of $57.18, suggesting potential for significant upside.
- Pharvaris has reported zero revenue for the past several quarters, highlighting a lack of commercial success.
- The company has consistently posted negative net income, with a total of -175.70 million in 2025, reflecting ongoing financial challenges.
- Pharvaris has a strong sell score of -16.00, indicating negative market sentiment and a bearish outlook.
Fundamentals
| Market cap | $2.18B | Enterprise value | $1.87B | Trailing P/E | — | Forward P/E | -10.25 |
| PEG | — | Price / book | 6.34 | Beta | -2.46 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -70.5% | ROA | -42.3% | Debt / equity | 0.00 |
| Current ratio | 11.94 | Free cash flow | -$90.36M | Analyst recommendation | strong_buy | Mean target | $57.28 |
| 52w high | $43.25 | 52w low | $20.65 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$47.8M | -$39.2M | -$46.7M | -$37.1M | -$45.5M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$50.8M | -$44.3M | -$47.6M | -$39.7M | -$40.4M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$176M | -$134M | -$101M | -$76.3M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$170M | -$146M | -$96.9M | -$86.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Pharvaris' Rare Disease Drug Meets Primary, Secondary Goals in Phase 3 Trial
2026-10-08 · Could Real-World HAE Oral Preference Data Be a Pivotal Signal for Pharvaris' (PHVS) Strategy?
2026-09-21 · Pharvaris Insider Sold Shares Worth $7,000,000, According to a Recent SEC Filing
2026-09-19 · What Does Pharvaris (PHVS) Phase 3 HAE Success Mean Now?
2026-09-19 · BioCryst Eyes $1B Rare-Disease Future Through External Innovation
2026-09-17 · Pharvaris Insider Sold Shares Worth $1,771,125, According to a Recent SEC Filing
2026-09-16 · Pharvaris Insider Sold Shares Worth $1,023,575, According to a Recent SEC Filing
2026-09-15 · PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
2026-09-10 · Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win?
Price (daily)
Full chart · RSI · MACD · patterns